A2BR facilitates the pathogenesis of H. pylori-associated GU by inducing oxidative stress through p38 MAPK phosphorylation

Tang, Weihong; Guan, Minchang; Li, Ze; Pan, Wei; Wang, Zhongmin

doi:10.1016/j.heliyon.2023.e21004

Cited by 1 publication

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with BAY60-6583 (an A2BR agonist) exacerbates gastric ulceration in rats, while PSB1115 (an A2BR antagonist) has the opposite effect. Incubation of GES-1 cells with agonists increased apoptosis, migration, and oxidative stress, effects that are reversed by inhibitors of the p38MAPK pathway ( Tang et al, 2023 ). In summary, combating H. pylori infection can be approached from various angles, and agents such as A2BR antagonists, TLR6 agonists, and SHP1 agonists hold promise as novel therapeutic strategies against H. pylori infection in the future.…”

Section: New Approachesmentioning

confidence: 99%

Novel therapeutic regimens against Helicobacter pylori: an updated systematic review

Huang,

Cao,

Cao

2024

Front. Microbiol.

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is a strict microaerophilic bacterial species that exists in the stomach, and H. pylori infection is one of the most common chronic bacterial infections affecting humans. Eradicating H. pylori is the preferred method for the long-term prevention of complications such as chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. However, first-line treatment with triple therapy and quadruple therapy has been unable to cope with increasing antibacterial resistance. To provide an updated review of H. pylori infections and antibacterial resistance, as well as related treatment options, we searched PubMed for articles published until March 2024. The key search terms were “H. pylori”, “H. pylori infection”, “H. pylori diseases”, “H. pylori eradication”, and “H. pylori antibacterial resistance.” Despite the use of antimicrobial agents, the annual decline in the eradication rate of H. pylori continues. Emerging eradication therapies, such as the development of the new strong acid blocker vonoprazan, probiotic adjuvant therapy, and H. pylori vaccine therapy, are exciting. However, the effectiveness of these treatments needs to be further evaluated. It is worth mentioning that the idea of altering the oxygen environment in gastric juice for H. pylori to not be able to survive is a hot topic that should be considered in new eradication plans. Various strategies for eradicating H. pylori, including antibacterials, vaccines, probiotics, and biomaterials, are continuously evolving. A novel approach involving the alteration of the oxygen concentration within the growth environment of H. pylori has emerged as a promising eradication strategy.

show abstract

Section: New Approachesmentioning

confidence: 99%